Frankfurt - Delayed Quote • EUR
OKYO Pharma Limited (OK10.F)
At close: May 24 at 9:15 AM GMT+2
Breakdown
TTM
3/31/2023
3/31/2022
3/31/2021
3/31/2020
Operating Expense
13,187.2000
13,187.2000
6,217.5660
3,366.2060
1,534.6460
Operating Income
-13,187.2000
-13,187.2000
-6,217.5660
-3,366.2060
-1,534.6460
Net Non Operating Interest Income Expense
-96.6870
-96.6870
--
-1.1230
46.9670
Other Income Expense
--
--
--
-11.1720
-132.6680
Pretax Income
-13,283.8870
-13,283.8870
-6,217.5660
-3,378.5010
-1,620.3470
Tax Provision
-12.2020
-12.2020
-786.5210
-24.9940
-76.2880
Net Income Common Stockholders
-13,271.6850
-13,271.6850
-5,431.0450
-3,353.5070
-1,544.0590
Diluted NI Available to Com Stockholders
-13,271.6850
-13,271.6850
-5,431.0450
-3,353.5070
-1,544.0590
Basic EPS
-0.61
-0.61
-0.36
-0.32
-0.00
Diluted EPS
-0.61
-0.61
-0.36
-0.32
-0.00
Basic Average Shares
22,257.0580
22,257.0580
15,064.8130
10,350.2710
595,474.0390
Diluted Average Shares
22,257.0580
22,257.0580
798,259.3560
10,350.2710
595,474.0390
Total Operating Income as Reported
--
--
--
-4,133.3498
-1,493.0308
Total Expenses
13,187.2000
13,187.2000
6,217.5660
3,366.2060
1,534.6460
Net Income from Continuing & Discontinued Operation
-13,271.6850
-13,271.6850
-5,431.0450
-3,353.5070
-1,544.0590
Normalized Income
-13,271.6850
-13,271.6850
-5,431.0450
-3,342.4176
-1,417.6372
Interest Income
--
--
--
--
48.1250
Interest Expense
96.6870
96.6870
--
1.1230
1.1580
Net Interest Income
-96.6870
-96.6870
--
-1.1230
46.9670
EBIT
-13,187.2000
-13,187.2000
-6,217.5660
-3,377.3780
-1,619.1890
EBITDA
-13,183.4030
-13,183.4030
-6,215.2350
-3,364.2670
-1,613.2100
Reconciled Depreciation
3.7970
3.7970
2.3310
13.1110
5.9790
Net Income from Continuing Operation Net Minority Interest
-13,271.6850
-13,271.6850
-5,431.0450
-3,353.5070
-1,544.0590
Total Unusual Items Excluding Goodwill
--
--
--
-11.1720
-132.6680
Total Unusual Items
--
--
--
-11.1720
-132.6680
Normalized EBITDA
-13,183.4030
-13,183.4030
-6,215.2350
-3,353.0950
-1,480.5420
Tax Rate for Calcs
0.0000
0.0000
0.0001
0.0000
0.0000
Tax Effect of Unusual Items
--
--
--
-0.0826
-6.2462
3/31/2020 - 5/25/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NXE0.F Seelos Therapeutics, Inc.
2.0000
0.00%
GEM.F GeNeuro SA
2.0900
-13.64%
RNUGF ReNeuron Group plc
0.0007
0.00%
ONPPF Oncopeptides AB (publ)
0.2650
-55.83%
AAVXF ABIVAX Société Anonyme
15.15
+38.36%
PXXLF Poxel S.A.
0.7000
+28.44%
RENE.L ReNeuron Group plc
3.3750
-2.17%
ALMDP.PA Medesis Pharma S.A.
0.9920
+1.22%
PHMMF Pharma Mar, S.A.
31.15
+16.01%
GNRO.PA GeNeuro SA
2.0600
-6.36%